Top of this page
Skip navigation, go straight to the content
In 2019 we entered the next phase of our Patient Value Strategy:
During this phase, we are accelerating our growth potential by further improving our ability to demonstrate differentiation of our medicines, by accelerating our development timelines through new approaches and by improving patients’ access to our key medicines.
The evolving COVID-19 pandemic is profoundly impacting our lives, and places tremendous strain on healthcare systems and society at large. Since the start of the crisis, UCB has taken measures to protect our colleagues around the world, to stand by patients, to help our communities and take our part in the global response to the pandemic. We know that it is our responsibility to help where we can make an impact. Find out what actions UCB has taken here.
bimekizumab positive Phase 3 results in psoriasis
zilucoplan
Staccato® alprazolam
bimekizumab in psoriatic arthritis, axial spondyloarthritis & hidradenitis suppurativa
rozanolixizumab in myasthenia gravis & immune thrombocytopenia
dapirolizumab pegol in lupus
Serving patients, our key medicines continued their growth in 2019.
To create a pipeline that will make a real difference in people’s lives, we focus on our key assets: our expertise in small and large molecules and our expertise in the fields of neurology and auto-immune diseases.
UCB is committed to sharing information on studies and making study results publicly accessible. You will find below links to the clinical studies (Phase 2-4) of our main R&D projects.
More information about our clinical studies index and our position paper are available here.
September 2020
IMNM: Immune-Mediated Necrotizing Myopathy
CIDP: Chronic Inflammatory Demyelinating Polyneuropathy
* In partnership with Biogen
Zilucoplan in COVID-associated ARDS by University of Ghent (Belgium) & Medical Research Council (U.K.)
Zilucoplan in amyotrophic lateral sclerosis (ALS) by HEALEY ALS Platform Trial